Cargando…

Proxy-Reported Quality of Life and Access to Nusinersen Among Patients with Spinal Muscular Atrophy in Saudi Arabia

BACKGROUND: The recent approval of innovative therapies for spinal muscular atrophy (SMA), such as nusinersen, has brought hope to patients and their families. OBJECTIVE: The aims of this study were to compare the characteristics and HRQoL of SMA patients treated with nusinersen and those treated wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	AlRuthia, Yazed, Almuaythir, Ghadah S, H Alrasheed, Hala, Alsharif, Wejdan R, Temsah, Mohamad-Hani, Alsohime, Fahad, Sales, Ibrahim, Alwhaibi, Monira, Bashiri, Fahad A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053517/ https://www.ncbi.nlm.nih.gov/pubmed/33880016 http://dx.doi.org/10.2147/PPA.S305849

Ejemplares similares

2020 Update to Spinal Muscular Atrophy Management in Saudi Arabia
por: Bashiri, Fahad A., et al.
Publicado: (2021)

The validation of a newly developed Arabic scale to assess patient-reported side-effects of antineoplastic agents
por: Alhaider, Reem, et al.
Publicado: (2019)

The Impact of Depression and Anxiety on Adult Cancer Patients’ Health-Related Quality of Life
por: Alwhaibi, Monira, et al.
Publicado: (2023)

Anxiety and depression and health-related quality of life among adults with migraine: a National Population-Based Study
por: Alwhaibi, Monira, et al.
Publicado: (2023)

Gender Differences in the Prevalence of Complementary and Alternative Medicine Utilization among Adults with Arthritis in the United States
por: Alwhaibi, Monira, et al.
Publicado: (2019)

Healthcare Expenditures Associated With Comorbid Anxiety and Depression Among Adults With Migraine
por: Alwhaibi, Monira, et al.
Publicado: (2021)

Pharmacy students’ attitudes toward patient safety in Saudi Arabia: a cross-sectional study
por: Alwhaibi, Monira, et al.
Publicado: (2020)

Medical Faculty’s and Students’ Perceptions toward Pediatric Electronic OSCE during the COVID-19 Pandemic in Saudi Arabia
por: Shaiba, Lana A., et al.
Publicado: (2021)

Assessing the pharmacy students’ knowledge of common medical terms after a curricular change in Saudi Arabia
por: AlRuthia, Yazed, et al.
Publicado: (2020)

Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018)

The cost-effectiveness of sequential versus standard triple therapy for Helicobacter pylori eradication in Saudi Arabia
por: AlRuthia, Yazed, et al.
Publicado: (2021)

Cost Effectiveness of ACEIs/ARBs versus Amlodipine Monotherapies: A Single-Center Retrospective Chart Review
por: AlRuthia, Yazed, et al.
Publicado: (2021)

Predictors and Direct Cost Estimation of Long Stays in Pediatric Intensive Care Units in Saudi Arabia: A Mixed Methods Study
por: Temsah, Mohamad-Hani, et al.
Publicado: (2021)

Nusinersen Treatment in Adults With Spinal Muscular Atrophy
por: Duong, Tina, et al.
Publicado: (2021)

Effect of new modalities of treatment on physicians’ management plan for patients with spinal muscular atrophy
por: Bashiri, Fahad A., et al.
Publicado: (2019)

Respiratory support attitudes among pediatric intensive care staff for spinal muscular atrophy patients in Saudi Arabia
por: Temsah, Mohamad-Hani A., et al.
Publicado: (2018)

Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy
por: Li, Qing
Publicado: (2020)

Nusinersen and Spinal Muscular Atrophies: Where are we in 2020?
por: Khadilkar, Satish V., et al.
Publicado: (2020)

The Relationship Between Health-Related Quality of Life and Trust in Primary Care Physicians Among Patients with Diabetes
por: AlRuthia, Yazed, et al.
Publicado: (2020)

The Impact of COVID-19 on Essential Medicines and Personal Protective Equipment Availability and Prices in Saudi Arabia
por: Aljadeed, Rana, et al.
Publicado: (2021)

Drug shortages in Saudi Arabia: Root causes and recommendations
por: Alruthia, Yazed S., et al.
Publicado: (2018)

The Prevalence of High-Risk Prescribing of Oral Non-Steroidal Anti-Inflammatory Drugs in Primary Healthcare: A Single-Centre Retrospective Chart Review Study
por: Assiri, Ghadah Asaad, et al.
Publicado: (2022)

Self-medication among adults with chronic health conditions: a population-based cross-sectional survey in Saudi Arabia
por: Alwhaibi, Monira, et al.
Publicado: (2023)

Fatigue in adults with spinal muscular atrophy under treatment with nusinersen
por: Kizina, K., et al.
Publicado: (2020)

Parents’ perspectives on nusinersen treatment for children with spinal muscular atrophy
por: van Kruijsbergen, Mette, et al.
Publicado: (2021)

Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study
por: Acsadi, Gyula, et al.
Publicado: (2021)

Nusinersen: A Review in 5q Spinal Muscular Atrophy
por: Hoy, Sheridan M.
Publicado: (2021)

Scoliosis in Spinal Muscular Atrophy Type 1 in the Nusinersen Era
por: Al Amrani, Fatima, et al.
Publicado: (2022)

Nusinersen mitigates neuroinflammation in severe spinal muscular atrophy patients
por: Nuzzo, Tommaso, et al.
Publicado: (2023)

Interprofessional Education Competition During the COVID-19 Pandemic at King Saud University: Benefits and Challenges
por: Alrasheed, Afnan, et al.
Publicado: (2021)

Nusinersen in type 0 spinal muscular atrophy: should we treat?
por: Tiberi, Eloisa, et al.
Publicado: (2020)

Nusinersen in pediatric and adult patients with type III spinal muscular atrophy
por: Pera, Maria Carmela, et al.
Publicado: (2021)

Correction to: Nusinersen: A Review in 5q Spinal Muscular Atrophy
por: Hoy, Sheridan M.
Publicado: (2021)

History of development of the life-saving drug “Nusinersen” in spinal muscular atrophy
por: Qiu, Jiaying, et al.
Publicado: (2022)

The relationship between trust in primary healthcare providers among patients with diabetes and levels of depression and anxiety
por: AlRuthia, Yazed, et al.
Publicado: (2020)

Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience
por: Haché, Manon, et al.
Publicado: (2016)

Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy
por: Stolte, Benjamin, et al.
Publicado: (2018)

Cost effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US
por: Thokala, Praveen, et al.
Publicado: (2020)

Nusinersen Wearing-Off in Adult 5q-Spinal Muscular Atrophy Patients
por: Osmanovic, Alma, et al.
Publicado: (2021)

Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy
por: Osmanovic, Alma, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h5ul7dsaes2pcucl7rq62dep5b